Eledon Pharmaceuticals, Inc. (ELDN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Eledon Pharmaceuticals, Inc. (ELDN) Healthcare & Pipeline Overview

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel therapies for autoimmune diseases, ALS, and transplant support. Their lead candidate, AT-1501, a humanized monoclonal antibody, targets CD40 Ligand and is undergoing Phase 2 trials, positioning Eledon within the competitive biotechnology landscape.

What Is the Investment Thesis for ELDN?

Eledon Pharmaceuticals, Inc. presents a notable research candidate within the biotechnology sector, driven by the potential of its lead product candidate, AT-1501. Currently in Phase 2 clinical trials for ALS and type 1 diabetes islet cell transplantation, AT-1501 targets CD40 Ligand, a key regulator of T cell activation. Positive clinical data from these trials could serve as a significant catalyst, potentially leading to accelerated regulatory pathways and future commercialization. The company's focus on addressing unmet needs in autoimmune diseases and neurodegenerative disorders positions it within high-growth therapeutic areas. However, the inherent risks associated with clinical-stage biopharmaceutical companies, including trial failures, regulatory hurdles, and financing requirements, must be carefully considered. Eledon's market capitalization of $213M reflects both the potential upside and the associated risks. Successful clinical development and strategic partnerships will be crucial in unlocking long-term value.

Based on FMP financials and quantitative analysis

ELDN Key Highlights

Lead product candidate AT-1501 is in Phase 2a clinical trials for ALS, targeting a significant unmet medical need.

• AT-1501 is also in Phase 2 clinical trials for islet cell transplantation in type 1 diabetes, offering a potential alternative to lifelong insulin dependence.
• The company rebranded from Novus Therapeutics, Inc. to Eledon Pharmaceuticals, Inc. in January 2021, signaling a strategic shift towards immunology.
• Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California, a hub for biotechnology innovation.
• The company has a market capitalization of $213M, reflecting its stage of development and potential for future growth.

Who Are ELDN's Competitors?

ELDN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ELDN's Key Strengths?

Lead product candidate AT-1501 targeting CD40 Ligand.

• Focus on unmet medical needs in autoimmune diseases, ALS, and transplant.
• Phase 2 clinical trials underway for ALS and type 1 diabetes.
• Experienced management team with expertise in drug development.

What Are ELDN's Weaknesses?

Clinical-stage company with no approved products.

• Reliance on a single lead product candidate.
• Limited financial resources.
• Small number of employees.

What Could Drive ELDN Stock Higher?

Data readout from Phase 2a clinical trial of AT-1501 in ALS.

• Data readout from Phase 2 clinical trial of AT-1501 in islet cell transplantation for type 1 diabetes.
• Enrollment and progress in ongoing clinical trials.
• Announcement of strategic partnerships or collaborations.
• Expansion of AT-1501 development into additional autoimmune indications.

What Are the Key Risks for ELDN?

Financial-distress signal — its Altman Z-Score of -4.17 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-96.8%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure to achieve positive clinical trial results.
• Regulatory delays or rejection of AT-1501.
• Competition from other companies developing similar therapies.
• Dependence on external funding to support clinical development.
• Patent challenges or loss of exclusivity for AT-1501.

What Are the Growth Opportunities for ELDN?

• Advancement of AT-1501 in ALS: The ALS market represents a significant opportunity for Eledon, given the limited treatment options currently available. The global ALS market is projected to reach $1.7 billion by 2030. Positive Phase 2a clinical trial results could pave the way for accelerated development and potential FDA approval, positioning AT-1501 as a valuable therapy for this devastating disease. Eledon's ability to demonstrate a meaningful clinical benefit in ALS patients will be critical for capturing market share.
• Development of AT-1501 in Type 1 Diabetes Islet Cell Transplantation: Eledon is targeting the type 1 diabetes market through islet cell transplantation, aiming to reduce or eliminate the need for lifelong insulin injections. The market for diabetes treatments is substantial, with a significant portion of patients seeking alternative therapies. Successful Phase 2 clinical trial results could position AT-1501 as a key component of islet cell transplantation protocols, driving adoption and revenue growth. The global diabetes market is expected to reach $49 billion by 2027.
• Expansion into Additional Autoimmune Indications: Eledon's AT-1501 has the potential to be developed for other autoimmune diseases beyond type 1 diabetes. The broader autoimmune disease market is vast and diverse, encompassing conditions such as rheumatoid arthritis, lupus, and multiple sclerosis. Eledon could explore the potential of AT-1501 in these indications through preclinical studies and clinical trials, expanding its pipeline and diversifying its revenue streams. The global autoimmune disease market is projected to reach $153 billion by 2028.
• Strategic Partnerships and Collaborations: Eledon can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of AT-1501. Collaborations can provide access to funding, expertise, and established distribution networks, increasing the likelihood of success. Potential partners could include companies with existing franchises in autoimmune diseases or transplant medicine. These partnerships can de-risk development and enhance market access upon approval.
• Exploration of Novel Immunomodulatory Targets: Eledon can leverage its expertise in immunology to identify and develop novel therapeutic targets beyond CD40 Ligand. This could involve exploring new mechanisms of action or developing combination therapies that synergize with AT-1501. A diversified pipeline of innovative therapies would reduce Eledon's reliance on a single product and enhance its long-term growth prospects. This requires investment in research and development and a commitment to scientific innovation.

What Are ELDN's Competitive Advantages?

• Patent protection for AT-1501 and other pipeline candidates.
• Clinical data demonstrating efficacy and safety of AT-1501.
• Expertise in immunology and drug development.
• Established relationships with key opinion leaders and clinical investigators.

What Does ELDN Do?

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for patients suffering from autoimmune diseases, amyotrophic lateral sclerosis (ALS), and those requiring organ or cell-based transplants. Founded with a vision to address unmet medical needs in these challenging therapeutic areas, Eledon has focused its efforts on advancing novel immunomodulatory approaches. The company's lead product candidate, AT-1501, is a humanized monoclonal antibody that targets CD40 Ligand, a key molecule involved in T cell activation and immune responses. AT-1501 is currently undergoing Phase 2a clinical trials for the treatment of ALS, a devastating neurodegenerative disease, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. These trials aim to evaluate the safety and efficacy of AT-1501 in modulating the immune system to prevent rejection of transplanted islet cells and to slow the progression of ALS. Formerly known as Novus Therapeutics, Inc., Eledon Pharmaceuticals, Inc. rebranded in January 2021 to reflect its renewed focus on immunology and its commitment to developing transformative medicines. Headquartered in Irvine, California, Eledon operates with a team of 31 employees, leveraging their expertise to advance its clinical programs and pipeline.

What Products and Services Does ELDN Offer?

• Develops medicines for autoimmune diseases.
• Focuses on therapies for amyotrophic lateral sclerosis (ALS).
• Creates treatments for patients requiring organ or cell-based transplants.
• Their lead product candidate is AT-1501, a humanized monoclonal antibody.
• AT-1501 targets CD40 Ligand, a molecule on T cells.
• Conducts Phase 2a clinical trials for AT-1501 in ALS.
• Conducts Phase 2 clinical trials for AT-1501 in islet cell transplantation for type 1 diabetes.

How Does ELDN Make Money?

• Develops and patents novel therapeutic candidates.
• Conducts preclinical and clinical trials to evaluate safety and efficacy.
• Seeks regulatory approval from agencies like the FDA.
• Potentially commercializes approved therapies directly or through partnerships.

What Industry Does ELDN Operate In?

Eledon Pharmaceuticals, Inc. operates within the dynamic and competitive biotechnology industry, which is characterized by rapid innovation, high regulatory hurdles, and significant investment in research and development. The market for autoimmune disease therapies is substantial and growing, driven by an increasing prevalence of these conditions and the development of novel biologic and targeted therapies. Similarly, the market for ALS treatments remains largely unmet, with limited therapeutic options available. Eledon's focus on AT-1501, a humanized monoclonal antibody targeting CD40 Ligand, positions it within the immunomodulation space, competing with other companies developing similar approaches. The success of Eledon will depend on its ability to demonstrate clinical efficacy, navigate regulatory pathways, and secure strategic partnerships.

Who Are ELDN's Key Customers?

• Patients suffering from autoimmune diseases.
• Patients diagnosed with amyotrophic lateral sclerosis (ALS).
• Patients requiring organ or cell-based transplants, specifically islet cell transplantation for type 1 diabetes.
• Healthcare providers and institutions involved in the treatment of these conditions.

How Eledon Pharmaceuticals, Inc. Is Valued

Eledon Pharmaceuticals, Inc. carries a market capitalization of $213M, placing it in the micro-cap category. Analyst price targets span from $5.00 to $5.00, with a consensus of $5.00. At the current price of $2.77, that implies approximately 81% upside potential. Relative to its peer group, ELDN's quantitative score of 28/100 is below the peer average of 77/100.

Company Profile

Eledon Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Irvine, United States.

Return on equity for Eledon Pharmaceuticals, Inc. stands at -96.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -53.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -29.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.44 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -17.6%, the inverse of the P/E and a quick read on earnings relative to price.

Eledon Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.17 places it in the distress zone, a signal of elevated financial risk.

Eledon Pharmaceuticals, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 7.3% below estimates on average.

Wall Street analysts project Eledon Pharmaceuticals, Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.93.

Over the past six months, Eledon Pharmaceuticals, Inc. insiders filed 4 SEC Form 4 transactions — 2 sales and 2 purchases. On net that is roughly 240K shares acquired (about $902K) — insiders putting money in tends to read as conviction.

ELDN Financials

ELDN Latest News

ELDN Analyst Consensus

ELDN MoonshotScore

What Investors Ask About Eledon Pharmaceuticals, Inc. (ELDN) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources